What should I do if I develop resistance to bosutinib/bosutinib?

Bosutinib/Bosutinib is an oral second-generation tyrosine kinase inhibitor mainly used to treat chronic myelogenous leukemia (CML) and other related diseases. Although bosutinib has shown good clinical efficacy, the problem of drug resistance still exists, which may affect the treatment effect and prognosis of patients. When faced with bosutinib resistance, a series of strategies need to be adopted.

First of all, if patients develop drug resistance, they should undergo genetic testing to identify whether there are BCR-ABL mutations associated with drug resistance. These mutations may lead to changes in the drug binding site, thereby affecting the efficacy of bosutinib. Common drug-resistant mutations include the T315I mutation. Identifying these mutations can help doctors develop appropriate subsequent treatment plans for patients.

After the resistance mechanism is determined, adjustment of the treatment regimen is crucial. For those patients who develop specific mutations, switching to other more effective targeted drugs may be a viable option. For example, for patients with the T315I mutation, third-generation tyrosine kinase inhibitors such as ponatinib may achieve good results. In addition, for patients who do not have specific mutations but are still resistant to bosutinib, multi-drug combination therapy can be considered to enhance the anti-cancer effect.

In addition, in-depth research on drug resistance mechanisms also provides new ideas for treatment. Changes in the tumor microenvironment, gene expression, and adaptive responses of tumor cells may affect the development of drug resistance. By monitoring tumor-related markers and biological pathways, treatment options can be adjusted in a timely manner to deal with drug resistance.

Individualized treatment of patients is also receiving more and more attention. Developing a personalized treatment plan based on the patient's specific conditions, including age, comorbidities, drug resistance types, etc., can improve the effectiveness and safety of treatment.

Reference materials:https://bosulif.pfizerpro.com/about/nccn-guidelines